Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's NVS Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

  • Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million.
  • Under the Accelerated Approval Program, continued approval may be contingent upon verification and description of clinical benefit from confirmatory evidence.
  • Read Next: Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis.
  • Alpelisib is already marketed as Piqray to treat a subset of advanced or metastatic breast cancer that is HR-positive, HER2-negative, and PIK3CA-mutated. 
  • Novartis ran a real-world study dubbed EPIK-P1, reviewing the medical charts of 57 patients. It found that those treated with Vijoice saw a reduction in the size of PROS lesions and improvements in related signs and symptoms.
  • The Company giant said it would conduct two additional Phase 2 studies: EPIK-P2 to assess safety, efficacy, and pharmacokinetics, and EPIK-P3 to look into long-term safety and efficacy for patients in EPIK-P1.
  • Price Action: NVS shares are up 0.77% at $88.85 during the premarket session on the last check Wednesday.

 

Posted In: BriefsBiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.